Navigation Links
New Study Results Provide Additional Data about Short- and,Long-Term Use of Desvenlafaxine Succinate in the Treatment of,Adults with Major Depressive Disorder

Nausea generally was transient, usually resolving within the first week. Nine patients (9 percent) had hypertension during the trial. Six patients reported a serious adverse event, none of which was considered related to desvenlafaxine succinate. Adverse events were noted as the cause of discontinuation from the study in about one-third of patients -- with the majority of discontinuations occurring in the first week. Study findings also showed that HAM-D17 mean total scores steadily decreased from baseline at Day 7 through Day 60 and continued to decrease through the end of the study.

Poster NR363: Ahmed S, et al. Switch from Venlafaxine to Desvenlafaxine Succinate Is Well-Tolerated in Patients with Major Depressive Disorder

In this study, patients taking venlafaxine ER were able to transition to desvenlafaxine succinate with a lower incidence of nausea than patients who switched from placebo to 200 mg/day of desvenlafaxine succinate. Furthermore, patients who switched from venlafaxine ER to desvenlafaxine succinate and those who remained on desvenlafaxine succinate were less likely to discontinue therapy than patients who switched from placebo to 200 mg/day of desvenlafaxine succinate (without titration).

Before joining the 10-week, open-label study, 517 patients completed one of two eight-week, double-blind, placebo-controlled, flexible-dose studies of desvenlafaxine succinate and venlafaxine ER. Patients who received either placebo (n=186) or venlafaxine ER (n=183) during the double-blind study began the open-label phase at 200 mg/day of desvenlafaxine succinate, while patients who took desvenlafaxine succinate (n=148) during the double-blind study remained on the same dose at the beginning of the open-label study. Based on clinical response, each patient's dose of desvenlafaxine succinate could be adjusted during the open-label study.

Study findings show that overall treatment-emergent adverse events reported during the 10-week study
'"/>




Page: 1 2 3 4 5 6 7 8

Related medicine technology :

1. Data Available From Erbitux Phase III Study in First-Line Treatment of Advanced Lung Cancer
2. Clinical Study Shows Regenecare Relieves Pain and Itching of Skin Rashes Caused by Widely Used Cancer Drugs
3. Cell Therapeutics, Inc. Management to Discuss Todays Announcement of Interim Pixantrone Study Results
4. Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy of BF-200 ALA In Actinic Keratosis
5. Reaction to Avandia Warnings Stronger Among Internists Than Endocrinologists, According to Study by GfK Market Measures
6. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
7. Actemra (tocilizumab) Third Phase III Study Results Show Significant Improvement in Symptoms of Patients with Rheumatoid Arthritis
8. Protox Announces Positive Clinical Data from Prostate Cancer Study
9. International ENDORSE Study Shows That the Majority of Hospitalized Patients Surveyed are at Risk for VTE and Many do not Receive Recommended VTE prophylaxis
10. New Study Shows That Extending Prophylaxis With Clexane / Lovenox (enoxaparin Sodium Injection) to 5 Weeks is More Effective Than 10 Days for Reducing the Risk of Venous Thromboembolism (VTE) in Acutely ill Medical Patients With Reduced Mobility
11. Genzyme Announces Data from First Phase 3 Study of Tolevamer in Patients with C. difficile Associated Diarrhea
Post Your Comments:
(Date:12/24/2014)... 24, 2014 Soligenix, Inc. (OTCQB: SNGX) ... developing products that address unmet medical needs in ... today that on December 24, 2014 it closed ... The Company raised approximately $2.3 million in gross ... the net proceeds from the offering to fund ...
(Date:12/24/2014)... DIEGO , Dec. 24, 2014  Conkwest, ... West, developing the proprietary Natural Killer (NK) cell-line ... that Dr. Patrick Soon-Shiong , NantWorks founder, ... a definitive agreement to purchase approximately $48 million ... connection with the investment, he will be named ...
(Date:12/24/2014)... N.J. and FARMINGTON, Conn. ... Technologies, Inc. (NYSE MKT: PTN), a biopharmaceutical company ... of diseases with significant unmet medical need and ... on a private placement of 2,050,000 shares of ... purchase 24,949,325 shares of its common stock.  Funds ...
Breaking Medicine Technology:Soligenix Announces Closing of Public Offering of Units 2Soligenix Announces Closing of Public Offering of Units 3Conkwest Announces $50m In Strategic Investments And Appoints NantWorks Founder, Dr. Patrick Soon-Shiong As Co-Chairman Of The Board 2Conkwest Announces $50m In Strategic Investments And Appoints NantWorks Founder, Dr. Patrick Soon-Shiong As Co-Chairman Of The Board 3Conkwest Announces $50m In Strategic Investments And Appoints NantWorks Founder, Dr. Patrick Soon-Shiong As Co-Chairman Of The Board 4Conkwest Announces $50m In Strategic Investments And Appoints NantWorks Founder, Dr. Patrick Soon-Shiong As Co-Chairman Of The Board 5Palatin Completes $20 Million Equity and $10 Million Debt Financings 2Palatin Completes $20 Million Equity and $10 Million Debt Financings 3Palatin Completes $20 Million Equity and $10 Million Debt Financings 4
... 14, 2011 Cytonome/ST, LLC, a developer and ... today announced a milestone in the high-speed detection ... identification of extremely rare target particles. Using Cytonome/ST,s ... system, the researchers were able to reliably identify ...
... Awarepoint Corporation , the leading provider ... health care, and MEDITECH , a leading ... announced a collaboration to integrate technologies to provide ... critical milestone tracking within MEDITECH,s enterprise-wide electronic health ...
Cached Medicine Technology:Awarepoint Corporation and MEDITECH Collaborate to Integrate Technology Platforms 2Awarepoint Corporation and MEDITECH Collaborate to Integrate Technology Platforms 3
(Date:12/25/2014)... This is a professional and in-depth study ... with a focus on the Chinese market. The report ... Sterilizers manufacturers and is a valuable source of guidance ... industry. This report provides a basic overview of the ... this part, the report presents the company profile, product ...
(Date:12/25/2014)... York (PRWEB) December 25, 2014 Product ... DePuy ASR hip recall ( http://www.consumerinjurylawyers.com/DePuy/ ) continue to ... According to an Order issued in the U.S. District ... Court will convene an open conference on January 7, ... United States Courthouse in West Palm Beach, Florida. The ...
(Date:12/25/2014)... Los Angeles, CA (PRWEB) December 25, 2014 ... Blaise Dolcemaschio was created in honor of a true ... premiere at two film festivals including the 24 hours of ... Film Festival in Bangladesh. , Actress, screenwriter and ... and helped produce this film together with her husband, ...
(Date:12/25/2014)... (PRWEB) December 25, 2014 When head lice ... themselves in a frenzy to get rid of it while ... families in Coral Gables now have the solution right in ... salon clinic location, Lice Troopers provides full spectrum head lice ... Coral Gable area, including Sunset, Key Biscayne, Brickell, Coconut Grove, ...
(Date:12/25/2014)... -- Overeating is common during the holidays, but there are ... says. "Don,t arrive at a party hungry. It may ... be attending a party, but deprivation leads to hunger, and ... Westchester Hospital in Mount Kisco, N.Y., said in a hospital ... day and even to have a snack before attending a ...
Breaking Medicine News(10 mins):Health News:Sterilizers Industry Global and Chinese Analysis for 2009-2019 Now Available at ReportsnReports.com 2Health News:Sterilizers Industry Global and Chinese Analysis for 2009-2019 Now Available at ReportsnReports.com 3Health News:Federal Court Overseeing DePuy ASR Hip Lawsuit Set to Convene Conference in January, Bernstein Liebhard LLP Reports 2Health News:Federal Court Overseeing DePuy ASR Hip Lawsuit Set to Convene Conference in January, Bernstein Liebhard LLP Reports 3Health News:The True 9/11 Hero Story “Color of Honor” Premieres in Germany and Bangladesh: Luciana Lagana Plays the Mother of the Lead and Co-Produces with Blaise Dolcemaschio. 2Health News:The True 9/11 Hero Story “Color of Honor” Premieres in Germany and Bangladesh: Luciana Lagana Plays the Mother of the Lead and Co-Produces with Blaise Dolcemaschio. 3Health News:Coral Gables Florida Gets Ready to Be Lice-Free with Lice Troopers 2
... INDIANAPOLIS, July 1 RealMed, a leader in web-based ... and payers, announced the launch of its new website. ... rewarding and informative experience. RealMed provides basic and detailed ... its service packages and their individual features and benefits. ...
... be Invalid Based on New Prior Art; JSA Technologies Patent ... YORK, July 1 Article One Partners, LLC has discovered ... drug patent, in closing out another round of Patent Studies. ... show the Crestor patent to be invalid, as verified by ...
... ... Eye Exam May Delay ,Age-related Macular Degeneration , ... San Francisco, CA (Vocus) July 1, 2009 -- This Summer, EyeCare ... summertime recipes that include foods rich in eye-healthy vitamins and antioxidants. Chefs including host of ...
... ... Inc., a leader in the manufacturing and development of clinical grade allogeneic adult stem ... and stem cell factors for the potential treatment of degenerations of the retina and ... ...
... July 1 The Frost & Sullivan "2009 ... is presented to Ireland-based Crospon for successfully using ... (endoluminal functional lumen imaging probe) imaging system. ... , "With EndoFLIP(R), Crospon has addressed the ...
... 30 The California Center for Cardiothoracic Surgery ... cutting edge heart operations. For patients facing cardiac issues, nothing ... to the delicate nature of cardiothoracic surgeries ... field is critical to a successful surgical outcome, which is ...
Cached Medicine News:Health News:Crestor Patent Invalidity Evidence Uncovered By Article One Partners Community 2Health News:Crestor Patent Invalidity Evidence Uncovered By Article One Partners Community 3Health News:Crestor Patent Invalidity Evidence Uncovered By Article One Partners Community 4Health News:This Summer, EyeCare America and Celebrity Chefs Want You to Feast Your Eyes on Eye Healthy Foods 2Health News:This Summer, EyeCare America and Celebrity Chefs Want You to Feast Your Eyes on Eye Healthy Foods 3Health News:This Summer, EyeCare America and Celebrity Chefs Want You to Feast Your Eyes on Eye Healthy Foods 4Health News:This Summer, EyeCare America and Celebrity Chefs Want You to Feast Your Eyes on Eye Healthy Foods 5Health News:Stemedica Discovers Significant Breakthrough in the Use of Stem Cells and Stem Cell Factors for the Treatment of Retinal Degeneration 2Health News:Stemedica Discovers Significant Breakthrough in the Use of Stem Cells and Stem Cell Factors for the Treatment of Retinal Degeneration 3Health News:Stemedica Discovers Significant Breakthrough in the Use of Stem Cells and Stem Cell Factors for the Treatment of Retinal Degeneration 4Health News:Stemedica Discovers Significant Breakthrough in the Use of Stem Cells and Stem Cell Factors for the Treatment of Retinal Degeneration 5Health News:Stemedica Discovers Significant Breakthrough in the Use of Stem Cells and Stem Cell Factors for the Treatment of Retinal Degeneration 6Health News:Stemedica Discovers Significant Breakthrough in the Use of Stem Cells and Stem Cell Factors for the Treatment of Retinal Degeneration 7Health News:Frost & Sullivan European Gastroenterology Technology Implementation of the Year Award Bestowed on Crospon 2Health News:Frost & Sullivan European Gastroenterology Technology Implementation of the Year Award Bestowed on Crospon 3Health News:Specialized California Medical Center (Heart411.com) Offers Top-Notch Cardiothoracic Surgery 2
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
Medicine Products: